Is FemTech, women's health tech finally being valued correctly, or still structurally underfunded?
- Nelson Advisors
- 4 minutes ago
- 10 min read
Benchmarking Women's Health Technology: Addressable Market Disparities, Valuation Multiples and Structural Capital Allocation
The global healthcare landscape is experiencing a re-evaluation of women’s health technology (commonly termed "femtech"). Historically treated as a niche sector concentrated around direct-to-consumer (DTC) reproductive apps and fertility solutions, women’s health tech has expanded into a complex, multi-specialty asset class spanning biopharma, AI-driven diagnostics, maternal care, midlife health, and chronic disease management.
Evaluating whether women's health technology is valued correctly or remains structurally underfunded requires examining market valuations, deal volume and capital deployment alongside the total addressable market (TAM) and economic burden.
While enterprise valuations and revenue multiples for mid-to-late-stage market leaders have achieved parity with general digital health and MedTech benchmarks, systemic capital allocation at the research and early-stage levels remains constrained relative to the sector's macroeconomic demographic footprint.
Addressable Market Dynamics and Macro Capital Allocation Disparities
The addressable market for women's health technology encompasses 50% of the global population, yet historical funding models have consistently miscalculated the breadth of this market by limiting scope to reproductive and maternal care. Macroeconomic analyses demonstrate that closing the women's health gap could inject $1 Trillion annually into the global economy by 2040. This value creation stems from addressing the 75 Million life-years lost annually due to women spending a disproportionate percentage of their lives in poor health or living with unmanaged disabilities.
Market research providers estimate the core global femtech market size between $45.6 Billion and $66.2 Billion in 2025, with projections anticipating growth to $145.5 Billion to $255.5 Billion by 2033–2035 at a Compound Annual Growth Rate (CAGR) ranging between 14.9% and 16.9%. When expanding the addressable domain to include health conditions that present differently, disproportionately, or exclusively in women, such as autoimmune disorders, cardiovascular disease, osteoporosis and Alzheimer's disease, the implied market size expands significantly.
Market Metric / Indicator | Value / Estimate | Source / Reference Base | Strategic Implication |
Global Femtech Market Size (2025) | $45.6B – $66.2B | Grand View Research / GMI | Baseline market capitalization across software, devices, and services. |
Projected Femtech Market Size (2033–2035) | $145.5B – $255.5B | Grand View Research / Research Nester | Expanding at a 14.9%–16.9% CAGR driven by enterprise adoption and digital health. |
Macro Economic Impact of Closing Gender Health Gap | $1.0 Trillion annually by 2040 | McKinsey Health Institute / WEF | GDP expansion resulting from increased labor force participation and reduced disease burden. |
Global Life-Years Lost to Female Health Disparities | 75 Million years annually | McKinsey / Research Nester | High burden of disease spent in poor health due to diagnostic delay and under-research. |
Share of Healthcare R&D Dedicated to Women’s Health | ~4.0% | PitchBook / Fortune Business Insights | Severe structural underfunding relative to a 50% demographic share. |
Share of Non-Cancer Women-Specific R&D Funding | ~1.0% | McKinsey / ASM | Extreme concentration in reproductive health, ignoring midlife, hormonal, and chronic care. |
Despite this addressable footprint, allocation metrics expose a persistent structural deficit in initial capital allocation. PitchBook data indicates that while women constitute roughly half of the world's population, only approximately 4% of overall healthcare research and development (R&D) is directed specifically toward women’s health conditions.
Furthermore, of the global R&D funding allocated to women's health, historically only 1% was directed toward non-cancer, women-specific conditions outside of fertility. This discrepancy illustrates that while product valuations at later stages are stabilizing, top-of-funnel innovation and early clinical research remain structurally underfunded relative to underlying biological and market demand.
Venture Capital Trajectory and Sub sector Deal Volume (2021–2026)
Venture capital deployment within the women's health sector has evolved through distinct market cycles. Following the initial pandemic expansion in 2020–2021, venture investment in dedicated women's health reached a peak of $2.6 Billion in 2024, reflecting a 55% year-over-year increase that outpaced investment growth across the broader healthcare industry. When evaluating capital deployed into broader conditions that disproportionately or differently affect women, total VC investment reached $10.7 Billion in 2024.
Transaction & Venture Capital Metric | 2021 | 2024 | 2025 | H1 2026 Trends |
Dedicated Women's Health VC Deployed | ~$0.8B | $2.6 Billion | ~$1.58B – $2.0B | Rebound trajectory driven by seed/Series A and AI deals. |
Expanded Scope VC Deployed | Historical baseline | $10.7 Billion | ~$10.6 Billion | Capital aligning with shared disease burden across populations. |
Healthtech Share of Sector VC | 54.0% | 38.0% | <38.0% | Contraction in consumer DTC apps; move to clinical networks. |
Biopharma Share of Sector VC | 12.0% | 34.0% – 35.0% | Resilient | Capital reallocation toward novel therapeutics and drug discovery. |
Precision Medicine VC Deployed | Undisclosed | $3.6 Billion | Expanding | High investor focus on biomarker diagnostics and personalized platforms. |
Women's Health Share of Total Digital Health VC | ~3.0% – 4.0% | 6.6% ($671M) | Stable | Highest proportional capture since 2021 peak. |
Following the record investments of 2024, capital deployment experienced a correction in 2025, falling to approximately $1.58 Billion to $2.0 Billion across the United States and Europe. This pullback mirrored broader macroeconomic trends in venture capital and digital health, where total U.S. digital health capital fell from pandemic spikes before normalising at $14.2 Billion in 2025. Early performance indicators in 2026 demonstrate a market rebound, characterised by deal consolidation and larger capital injections into scaled, defensible platforms.
A significant second-order insight involves the subsector shift within women's health funding. Between 2021 and 2025, capital allocation shifted away from pure-play direct-to-consumer (DTC) wellness applications toward high-acuity clinical platforms, specialty care networks, and biopharmaceuticals. In 2021, healthtech solutions captured 54% of all women's health VC dollars, while biopharma secured only 12%. By 2024, healthtech’s share declined to 38%, whereas biopharma funding surged to 34%–35%. Concurrently, precision medicine capital grew to $3.6 billion in 2024, up from $1.4 Billion in 2023, reflecting investor demand for clinical validation, proprietary IP and reimbursement pathways.
Capital deployment in the sector exhibits significant deal concentration. Analogous to the broader digital health market, where 12 mega deals captured nearly 60% of total quarterly funding, women's health funding is increasingly concentrated among market leaders. Platform enterprises such as Maven Clinic ($420 million total capital raised), Kindbody ($330 Million), Flo Health ($200 Million raised in Series C funding), and Willow ($175 Million Series C) capture an outsized share of venture dollars.
Late-stage funding events in 2025 and H1 2026 highlight this capital concentration. Midi Health, a specialised virtual care platform focused on perimenopause, menopause, and metabolic health, completed a $100 Million Series D financing round in 2026, propelling its valuation to $1.0 billion. Similarly, platforms such as Pomelo Care and Natural Cycles secured late-stage growth rounds, illustrating that institutional capital favours scalable models integrated with enterprise health plans and employer benefit channels over fragmented DTC tools.
Comparative Valuation Multiples, Capital Efficiency and the AI Premium
Private market valuations for women's health technology companies demonstrate a split between baseline assets and specialised platforms.
Healthcare Sector / Sub-Vertical | Median EV / Sales (Revenue) | Upper Quartile EV / Sales | Median EV / EBITDA | Valuation Benchmarking Implication |
FemTech Market Benchmark | 4.4× [cite: 6] | 5.0× – 6.5× [cite: 6, 24] | 23.2× [cite: 6] | Aligns with general digital health and tech-enabled services. |
General HealthTech / Telehealth | 4.0× – 4.8× | 6.0× – 8.0× | 10.0× – 14.0× | High-growth, AI-integrated platforms command top-tier pricing. |
European MedTech / Devices | 4.0× – 6.0× | 6.0× – 8.0× | 10.0× – 14.0× | Driven by regulatory clearance and EHR integration. |
Health & Wellness / DTC | 1.1× | 2.0× – 3.5× | 10.2× | Compressed revenue multiples due to user acquisition friction. |
Vertical Healthcare SaaS | 3.6× – 6.3× | 8.0× – 15.0× | 18.8× | Premium applied to high retention (>110% NRR) and workflow integration. |
A notable divergence in valuation premium emerges when analysing Artificial Intelligence integration. Silicon Valley Bank proprietary market analyses show that AI-enabled women's health startups command a median pre-money valuation of $35 Million, nearly triple the valuation of non-AI counterparts within the same sector.
This premium is driven by application-specific AI deployments. Rather than focusing purely on generative chatbots or back-office operational automation, AI in women's health is applied heavily toward risk prediction, diagnostic enhancement, and clinical decision support. Examples include AI-enhanced mammogram and Pap smear screening, predictive analytics for preeclampsia, personalized endo-metabolic tracking, and peri-menopause symptom management platforms such as IdentifyHer's Peri wearable or Mind & Mom's maternal predictive platforms. These diagnostic tools target systemic clinical gaps where historical datasets missed sex-specific risk factors.
Valuation metrics show that once a women's health startup scales past Series B and demonstrates enterprise reimbursement validation (e.g., contracts with payers or Fortune 500 employer benefits programs), public and private markets value the company on standard SaaS or tech-enabled healthcare service multiples. Underfunding is therefore not primarily a function of structural valuation discounts applied to mature revenues, but rather a bottleneck in seed and Series A capital allocation.
Structural Impediments, Database Misclassification and Exit Dynamics
The thesis that women's health technology remains structurally underfunded is supported by institutional pipeline mechanics, regulatory barriers, and industry categorization errors.
A primary structural friction is the systematic misclassification of women’s health assets in primary financial databases such as PitchBook, Crunchbase, and deal tracking platforms. Historical research by AOA Dx ("Follow the Exits: Why Women's Health Is a Smart Bet in Healthcare") revealed that between 2000 and 2025, there were 272 publicly announced exits in the women's health domain, representing over $100 billion in cumulative realised exit value and creating 27 distinct unicorns.
However, because traditional database taxonomy lacks standalone "Women's Health" tags across life sciences, companies developing therapeutics for ovarian cancer, diagnostic assays for endometriosis, or devices for pelvic health were routinely categorised under general terms like "Oncology," "Diagnostics," or "Medical Equipment". Consequently, institutional investors running quantitative screening models failed to capture the historical returns, median IRR, and exit multiples of the sector, creating an artificial perception of category illiquidity.
To address this structural funding gap, specialized venture capital funds have emerged. These firms deploy targeted capital at early stages, demonstrating category expertise and establishing specialised syndicates.
Specialised VC Firm | Estimated AUM / Fund Status | Primary Investment Stage | Key Portfolio Assets & Strategic Focus |
SteelSky Ventures | $72M – $73M AUM | Late Seed, Series A & B | Largest dedicated women's health fund globally. Portfolio includes Origin, Raydiant Oximetry, Zipline, Twenty Eight Health. |
Amboy Street Ventures | $20M Fund I | Seed & Series A | Focuses on women's health, hormonal health, and sexual wellness. Portfolio includes Evvy, Alloy, Hey Jane, Contraline. |
Coyote Ventures | Early-Stage Dedicated | Seed Stage | Focuses on digital health and health equity for overlooked populations. |
RH Capital | Dedicated Impact VC | Seed to Series A/B | Focuses on maternal health equity and reproductive healthcare access. Portfolio includes Bloomlife, Ovia Health, Nurx. |
FemHealth Ventures | Dedicated Specialty VC | Early Stage | Targets conditions affecting women exclusively, disproportionately, or differently. |
While these specialised funds provide crucial seed capital, their total Assets Under Management (AUM), such as SteelSky's $72 Million tp $73 Million fund, remain modest relative to multi-billion-dollar generalist life sciences and technology funds. As a result, promising startups face a capital bottleneck when transitioning from early-stage proof-of-concept rounds to Series B and C growth rounds, where check sizes of $30 Million to $100 Million require generalist institutional participation.
Additional structural barriers include regulatory ambiguities and reimbursement challenges. Regulatory agencies have historically lacked standardized evaluation frameworks for digital therapeutics and algorithms specific to women's biology, such as software-as-a-medical-device (SaMD) classifications for cycle-based diagnostics or fertility tracking.
Furthermore, shifting business models from high-churn DTC subscription channels to enterprise B2B sales requires building clinical evidence, executing health economics and outcomes research (HEOR) studies, and securing CPT reimbursement codes. Startups unable to navigate this transition experience revenue compression, trading at single-digit revenue multiples, typical of consumer wellness rather than the higher multiples awarded to clinically validated digital health systems.
Definitive Market Conclusions and Strategic Imperatives
The quantitative data supports a definitive conclusion regarding whether women's health technology is valued correctly or structurally underfunded.
At the growth-stage and exit level, successful platforms are valued correctly. When women's health enterprises cross revenue thresholds of $10 Million to $20 Million ARR, maintain strong net expansion, and secure payer or enterprise coverage, they command enterprise multiples that mirror the broader digital health and MedTech sectors. Category leaders like Midi Health, Maven Clinic, and Flo Health demonstrate that public and private markets reward scaled execution without imposing a category discount.
At the system level, however, the category remains structurally undercapitalised relative to total market demand. The allocation of just 4% of total healthcare R&D, combined with venture funding capturing roughly 6.6% of overall digital health dollars, indicates a capital gap when benchmarked against a target demographic that controls 80% of healthcare purchasing decisions and represents a $1 Trillion economic opportunity. Early-stage ventures suffer from capital access bottlenecks due to historical database misclassification, small specialised fund AUMs, and a shortage of growth-stage generalist capital.
To capture the arbitrage created by this structural repricing, institutional investors and healthcare leaders must execute targeted strategic pivots. Institutional Limited Partners (LPs) and generalist venture capital firms must update quantitative screening taxonomies to track misclassified women's health assets across oncology, neurology and immunology, unlocking access to historical category returns that exceed $100 billion in realised exit value.
Concurrently, healthcare enterprise operators and corporate health plans should accelerate value-based care integration and coverage for specialised platforms, particularly in midlife menopause care and maternal outcomes tracking, to lower long-term claims expenses and capture measurable return on investment in employee retention.
Finally, founders and clinical developers must prioritise early clinical validation, proprietary diagnostic data collection, and AI-enabled risk prediction pathways over direct-to-consumer acquisition models, as building defensible clinical evidence remains the most reliable mechanism to unlock biopharma partnership capital and command premium market valuations.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments